The PROTECT VIII trial is made to investigate whether BAY94-9027.

Bayer commences enrollment in BAY94-9027 Stage II/III trial for hemophilia A Bayer Health care today announced the business has began to enroll patients within an international Stage II/III trial to judge its investigational substance BAY94-9027 for the treating hemophilia A. The PROTECT VIII trial is made to investigate whether BAY94-9027, a recombinant individual element VIII , can prolong the duration of safety from bleeds and invite for less regular Infusions when utilized prophylactically, while also to be able to treat severe bleeding events. BAY94-9027 offers been engineered to increase the half-existence of rFVIII while preserving biologic activity by inserting an individual cysteine site to its surface area, which acts as an attachment site for a polyethylene glycol polymer http://sildalis.org .